Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rebif’s New Formulation Delayed By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck Serono says it is in discussions with FDA to answer outstanding questions over the new formulation of the multiple sclerosis drug.

You may also be interested in...

Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics

German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.

Merck KGaA Buys Serono, Gaining U.S. Commercial Organization

Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.

Serono Says New Rebif Formulation Could Increase Tolerability

Firm files the human serum albumin-free and fetal bovine serum-free interferon beta-1a in the U.S. and the EU.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts